Longitude Capital
  • ABOUT
  • TEAM
  • PORTFOLIO
  • NEWS
  • CONTACT
  • LP LOGIN
Select Page

Landmark New England Journal of Medicine Publication Reports Positive Results From PROMISE II Pivotal Trial Showing that LimFlow System Saves Most Patients with End-stage Peripheral Artery Disease From Major Amputation

by Seini Moimoi | Mar 30, 2023 | Portfolio News

89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks

by Seini Moimoi | Mar 22, 2023 | Portfolio News

Somatus Expands Partnership with Inova to Further Enhance Care and Improve Outcomes for Patients

by Seini Moimoi | Mar 9, 2023 | Portfolio News

Avenge Bio Receives Positive Feedback from Pre-IND FDA Meeting on Development Path for AVB-001 Mesothelioma Program and Provides Pipeline Update

by Seini Moimoi | Mar 9, 2023 | Portfolio News

Ceribell Named to Fast Company’s 2023 List of the World’s Most Innovative Companies

by Seini Moimoi | Mar 2, 2023 | Portfolio News

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

by Seini Moimoi | Feb 21, 2023 | Portfolio News

Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701

by Seini Moimoi | Feb 16, 2023 | Portfolio News

Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria

by Seini Moimoi | Jan 30, 2023 | Portfolio News

Cohere Health Introduces Cohere Unify™ Intelligent Prior Authorization

by Seini Moimoi | Jan 25, 2023 | Portfolio News

Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)

by Seini Moimoi | Jan 11, 2023 | Portfolio News

« Older Entries

Media Contact

Maggie Jamison

mjamison@longitudecapital.com

650-854-5700

  • Facebook
  • Twitter
  • Google
  • RSS
footer-logo

LP Login

© 2023 Longitude Capital. All rights reserved.
  • Privacy Policy
  • Disclaimer